Echo gets European go-ahead for needle-free Symphony trial; Norwegian nano-needles could force cellular delivery;

> Echo Therapeutics' ($ECTE) Symphony CGM System, a needle-free delivery device the company is developing for use as a glucose monitoring system, garnered acceptance from its Notified Body in Europe for a clinical trial plan. Release

> Nano-needles developed by Norwegian researchers may be used to force drugs into cells by impaling them from a tiny field of spikes. Article

> Arrowhead Research ($ARWR) filed with the FDA to begin a Phase I trial of its RNAi-based candidate for the treatment of hepatitis B. Release

> Drug-delivery company Acrux filed a lawsuit over claims that Perrigo Israel Pharmaceuticals infringed a patent of its delivery platform, Axiron. Release

> Swedish pharmaceutical company Oasmia has developed a combination cancer therapy with a unique drug-delivery system that allows the products to effectively act in tandem. WSJ report